Evidence map›Paper›PMID 41816338›Full record

ArticleFrontiers in immunology2026

IL 15 enhances preclinical efficacy of anti-core 1 O-glycans monoclonal antibody NEO-201 against human endometrial and ovarian cancer.

Jamie Hur, Massimo Fantini, Lidia Hernandez, Soumya Korrapati, Elijah F Edmondson, Maggie Cam, Mayank Tandon, Christopher B Cole, Kwong Y Tsang, Philip M Arlen and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jamie HurWomen's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Massimo FantiniPrecision Biologics, Inc., Bethesda, MD, United States.
Lidia HernandezWomen's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Soumya KorrapatiWomen's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Elijah F EdmondsonMolecular Histopathology Laboratory, Laboratory Animal Sciences Program, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.
Maggie CamCenter for Cancer Research Collaborative Bioinformatics Resource (CCBR), National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Mayank TandonCenter for Cancer Research Collaborative Bioinformatics Resource (CCBR), National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Christopher B ColeWomen's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Kwong Y TsangPrecision Biologics, Inc., Bethesda, MD, United States.
Philip M ArlenPrecision Biologics, Inc., Bethesda, MD, United States.
Christina M AnnunziataWomen's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Maria Pia MorelliDepartment of Gastrointestinal Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Resistance of gynecological cancers to immunotherapy is due to their ability to impair the cytotoxic activity of immune cells. One strategy to overcome this resistance is the combination of different types of immunotherapies with different mechanisms of action and different targets. The disruption of O-glycosylation pathway in ovarian and endometrial cancer is associated with cancer growth, metastasis, and poor prognosis. Methods: In this study we treated Results: In this study we demonstrated that IL-15 enhanced ADCC mediated by NEO-201 Conclusions: The ability of IL-15 to enhance NEO-201 efficacy, with NK cells as effectors, supports the hypothesis of combining NEO-201 and IL-15 with NK cell therapy (i.e. IL-15-secreting CAR-NK cells with a longer IL-15

Indexed as

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalEndometrial NeoplasmsInterleukin-15Ovarian NeoplasmsPolysaccharidesAnimalsAntibody-Dependent Cell CytotoxicityCell Line, TumorFemaleHumansKiller Cells, NaturalMiceXenograft Model Antitumor AssaysAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalIL15 protein, humanInterleukin-15Polysaccharidesantibody-dependent cellular cytotoxicitygynecological cancersIL-15monoclonal antibodynatural killer cellNEO-201O-glycans

Identifiers

PMID41816338
PMCPMC12971406

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.